Serum FGF21 and RBP4 levels in patients with chronic hepatitis C

References

• Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Pupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005;54:1003–8.
   PubMed Web of Science ®Google Scholar
• Yoneda M, Saito S, Ikeda T, Fujita K, Mawatari H, Kirikoshi H, Hepatitis C virus directly associates with insulin resistance independent of the visceral fat area in nonobese and nondiabetic patients. J Viral Hepat 2007;14:600–7.
   PubMed Web of Science ®Google Scholar
• Adinolfi LE, Durante-Mangoni E, Zampino R, Ruggiero G. Review article: hepatitis C virus-associated steatosis – pathogenic mechanism and clinical implications. Aliment Pharmacol Ther 2005;22(Suppl 2):52–5.
   PubMedGoogle Scholar
• Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000;133:592–9.
   PubMed Web of Science ®Google Scholar
• Perlemuter G, Sabile A, Letteron P, Strathdee SA, Szklo M, Thomas DL. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 2002;16:185–95.
   PubMed Web of Science ®Google Scholar
• Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, Insulin resistance is associated with chronic hepatitis C infection and fibrosis progression. Gastroenterology 2003;125:1695–704.
   PubMed Web of Science ®Google Scholar
• Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, Fernández-Rodríguez CM, Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005;128:636–41.
   PubMed Web of Science ®Google Scholar
• Kukla M, Zwirska-Korczala K, Gabriel A, Waluga M, Warakomska I, Szczygiel B, Chemerin, vaspin and insulin resistance in chronic hepatitis C. J Viral Hepat 2010;17:661–7.
   PubMedGoogle Scholar
• Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009;58:250–9.
   PubMed Web of Science ®Google Scholar
• Leandro G, Mangia A, Hui J, Fobris P, Rubia-Brandt L, Colloredo G, Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006;130:1636–42.
   PubMed Web of Science ®Google Scholar
• Bernsmeier Ch, Heima MH. Insulin resistance in chronic hepatitis C: mechanisms and clinical relevance. Swiss Med Wkly 2009;139:678–84.
   PubMed Web of Science ®Google Scholar
• Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009;50:957–69.
   PubMed Web of Science ®Google Scholar
• Kukla M, Zwirska-Korczala K, Hartleb M, Waluga M, Chwist A, Kajor M, Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scand J Gastroenterol 2010;45:235–42.
   PubMed Web of Science ®Google Scholar
• Chen W, Li L, Yang G, Li K, Qi XY, Zhu W, Circulating FGF-21 levels in normal subjects and in newly diagnosed patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2008;116:65–8.
   PubMed Web of Science ®Google Scholar
• Zhang X, Yeung D, Karpisek M, Stejskal D, Zhou ZG, Liu F, Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008;57:1246–53.
   PubMed Web of Science ®Google Scholar
• Chavez A, Molina-Carrion M, Abdul-Ghani M, Filli F, De Fronco RA, Tripathy D. Circulating fibroblast growth factor 21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 2009;32:1542–6.
   PubMed Web of Science ®Google Scholar
• Mraz M, Bartlova M, Lacinova Z, michalsky D, Kasalycky M, Halizikowa D, Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf) 2009;71:369–75.
   PubMed Web of Science ®Google Scholar
• Kharitonenkov A, Shiyanova T, Koester A, Ford AM, Micanovic R, Galbreath EJ, FGF-21 as a novel metabolic regulator. J Clin Invest 2005;115:1627–35.
   PubMed Web of Science ®Google Scholar
• Yilmaz Y, Eren F, Yonal O, Kurt R, Aktas B, Ataizi C, Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur J Clin Invest 2010;40:887–92.
   PubMed Web of Science ®Google Scholar
• Dushay J, Chui PC, Gopalakrishnan GS, Vraela-Rey M, Craweley M, Fisher MF, Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010;139:456–63.
   PubMed Web of Science ®Google Scholar
• Domingo P, Gallego-Escuredo JM, Domingo JC, Gutierrez MM, Mateo MG, Fernandez I, Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients. AIDS 2010;24:2629–37.
   PubMed Web of Science ®Google Scholar
• van Dam RM, Hu FB. Lipocalins and insulin resistance: etiological role of retinol-binding protein 4 and lipocalin-2? Clin Chem 2007;53:5–7.
   PubMed Web of Science ®Google Scholar
• Blaner WS. Retinol-binding protein: the serum transport protein for vitamin A. Endocr Rev 1989;10:308–16.
   PubMed Web of Science ®Google Scholar
• Desvergne B. RXR: from partnership to leadership in metabolic regulations. Vitam Horm 2007;75:1–32.
   PubMed Web of Science ®Google Scholar
• Petta S, Cammà C, Di Marco V, Allesi N, Barbaria F, Cabibi D, Retinol binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis C virus genotype 1. Hepatology 2008;48:28–37.
   PubMed Web of Science ®Google Scholar
• von Eynatten M, Lepper PM, Liu D, Lang K, Bauman M, Nawroth A, Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease. Diabetologia 2007;50:1930–7.
   PubMedGoogle Scholar
• Broch M, Vendrell J, Ricart W, Richart C, Fernandez-Real JM. Circulating retinol-binding protein-4, insulin sensitivity, insulin secretion, and insulin disposition index in obese and nonobese subjects. Diabetes Care 2007;30:1802–6.
   PubMed Web of Science ®Google Scholar
• Wu H, Jia W, Bao Y, Lu J, Zhu J, Wang R, Serum retinol binding protein 4 and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2007;79:185–90.
   PubMedGoogle Scholar
• Petta S, Tripodo C, Grimaudo S, Cabibi D, Camma C, Di Cristina A, High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis. Digest Liver Dis 2011;43:404–10.
   Google Scholar
• Yagmur E, Weiskirchen R, Gressner AM, Trautwein C, Tacke F. Insulin resistance in liver cirrhosis is not associated with circulating retinol-binding protein 4. Diabetes Care 2007;30:1168–72.
   PubMedGoogle Scholar
• Bahr MJ, Boeker KH, Manns MP, Tietge UJ. Decreased hepatic RBP4 secretion is correlated with reduced hepatic glucose production but is not associated with insulin resistance in patients with liver cirrhosis. Clin Endocrinol (Oxf) 2009;70:60–5.
   PubMed Web of Science ®Google Scholar
• Iwasa M, Hara N, Miyachi H, Tanaka H, Takeo M, Fujita N, Patients achieving clearance of HCV with interferon therapy recover from decreased retinol-binding protein 4 levels. J Viral Hepat 2009;16:716–23.
   PubMed Web of Science ®Google Scholar
• Huang JF, Dai CY, Yu ML, Shin SJ, Hsieh MY, Huang CF, Serum retinol-binding protein 4 is inversely correlated with disease severity of chronic hepatitis C. J Hepatol 2009;50:471–8.
   PubMed Web of Science ®Google Scholar
• Scheuer PJ. The nomenclature of chronic hepatitis: time for a change. J Hepatol 1995;22:112–14.
   PubMedGoogle Scholar
• Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Terti BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467–74.
   PubMed Web of Science ®Google Scholar
• Li H, Fang Q, Gao F, Fan J, Zhou J, Wang X, Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol 2010;53:934–40.
   PubMed Web of Science ®Google Scholar
• Kukla M, Gabriel A, Sabat D, Liszka L, Wilk M, Petelenz M, Association between liver steatosis and angiogenesis in chronic hepatitis C. Pol J Pathol 2010;3:154–60.
   Google Scholar
• Palmentieri B, de Sio I, La Mura V, Masarone M, Vecchione R, Torella R, The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis 2006;38:485–9.
   PubMedGoogle Scholar
• Yao-Borengasser A, Varma V, Bodles AM, Rasouli N, Phanavanh B, Lee MJ, Retinol binding protein 4 expression in humans; relationship to insulin resistance, inflammation, and response to pioglitazone. J Clin Endocrinol Metab 2007;92:2590–7.
   PubMed Web of Science ®Google Scholar
• Balagopal P, Graham TE, Kahn BB, Altomare A, Funanage V, George D. Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: association with subclinical inflammation. Diabetes Care 2007;30:1173–8.
   PubMedGoogle Scholar